Sign in

    Lee Chen

    Managing Director of Equity Research at H. C. Wainwright

    Lee Chen is a Managing Director of Equity Research at H.C. Wainwright, specializing in biotechnology and pharmaceutical equity analysis. He covers companies including Co-diagnostics and maintains a TipRanks success rate of 36.1% with a total average return of -9.5% over the past year. Dr. Chen has built his career as a specialist in equity research, having joined H.C. Wainwright in a senior capacity after prior analyst roles; his research frequently informs investment decisions in the biotech sector. His professional credentials include extensive experience in investment research, but current FINRA registration and securities licenses could not be confirmed.

    Lee Chen's questions to Coherus Oncology (CHRS) leadership

    Lee Chen's questions to Coherus Oncology (CHRS) leadership • Q2 2025

    Question

    Asked for an update on the durability of response from the initial first-line HCC triplet study and inquired about the planned comparator arm for a future Phase III trial in the same indication.

    Answer

    The final data from the initial HCC study was presented in January, showing a 38% ORR, 17% CR, and durable responses, with an 8.9-month PFS. The ongoing study uses their own PD-1, Toripalumab. The next trial will likely be a Phase 2/3 study comparing their triplet against the standard of care, Atezo/Bev, with the decision informed by data expected in H1 2026.

    Ask Fintool Equity Research AI